Healthcare Industry News: metabolic disease
News Release - April 15, 2010
Taligen Appoints Industry Leader, John Maraganore, as DirectorCAMBRIDGE, Mass.--(HSMN NewsFeed)--Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced the appointment of John Maraganore, Ph.D., CEO of Alnylam Pharmaceuticals to its Board of Directors.
“Dr. Maraganore is a proven leader with one of the best strategic minds in the biotechnology industry,” said Dr. Timothy Mills, Chairman of the Board of Taligen and Managing Director with Sanderling Ventures. “John will help us to navigate our way through a broad set of opportunities with Taligen’s unique products and platform technologies.”
John Maraganore joined Alnylam in December 2002. Prior to Alnylam, he served as an officer and Senior Vice President of Product Development at Millennium Pharmaceuticals with responsibility for the company’s oncology, cardiovascular, inflammation and metabolic disease franchises. Prior to Millennium, he served in senior roles at Biogen, Inc. (now Biogen Idec, Inc.) including Director of Molecular Biology and Director of Market and Business Development where he invented and led the discovery and development of Angiomax™. Dr. Maraganore also held scientific management positions at Zymogenetics, Inc. and The Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Maraganore is Chairman of Regulus Therapeutics and a Director of Archemix and Macrogenetics. He is also a member of the Research Advisory Board of the Beth Israel Deaconess Hospital and a member of the Biotechnology Industry Organization Board.
“Taligen is a clear leader in the field of complement system biology, an area of great scientific promise. Taligen has assembled a team of highly experienced scientists, drug developers and business professionals and I am honored to contribute my experience and insights at this exciting stage of the Company’s development,” said Dr. Maraganore.
“We are very excited that Dr. Maraganore has joined our Board, particularly as we plan to advance our lead programs into clinical trials,” said Abbie Celniker, Ph.D., President and CEO of Taligen. “John’s leadership and success in the biotechnology field will be a great asset, and we are fortunate to have him as part of the Taligen organization.”
About Taligen Therapeutics
Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen’s targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit www.taligentherapeutics.com.
Source: Taligen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.